Published in Drug Week, September 26th, 2003
The net income and EPS results are absent a $12.2 million tax-effected special charge reported during fiscal 2003 associated with research and development collaborations. Net income and EPS, including the special charges associated with the research and development collaborations, were $51.3 million and $1.82 per diluted share, respectively.
In fiscal 2002, Medicis reported net revenues of $212.8 million with net income of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.